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Background: Several approaches to clinical trial monitoring, including the Risk Based Monitoring (RBM)
are aimed at the protection of the human subjects (safety), improved data quality, and ultimately,
reducing the cost of drug development and operations. There exists minimal evidence globally about the
perceptions and the level of conﬁdence among the clinical staff on the merits of RBM. The present study
assessed the perception among clinical research staff globally (developed and emerging countries) on the
applicability and adaptability of RBM.
Methods: An electronic questionnaire survey consisting of twelve items was developed, validated, and
then circulated globally via email to three thousand clinical research staff members at various investi-
gational sites. This survey collected information on the use of RBM and factors that relate to clinical trial
cost, data quality, subject safety, and the readiness to adopt RBM practices. The survey responses were
summarized and analyzed by using the information e.g. responder's age, sex, clinical research role, global
location, and experience in clinical research trials.
Results: Responses were received from ten countries, six emerging and four developed. Of the 3000
surveys sent to emerging (1,000) and developed (2,000) countries, a total response of 595 (261 vs 334)
participants was received, respectively. The emerging versus developed group had 100 vs 137 partici-
pants with complete responses (CR); 34 vs 35 participants with partial responses (PR); and 127 vs 162
participants were disqualiﬁed with no exposure (NE) responses. About 67% of the overall responders
were investigators, followed by 23%, 10% coordinator and other staff respectively. There was not sig-
niﬁcant difference in feedback between the researchers in developing versus emerging countries
(p ¼ 0.20) with regards to their perception of RBM reducing the overall cost of conducting a clinical
research. Responders from emerging countries had a more favorable response than in the developed
countries. Similarly, when asked if RBM will be more effective in addressing data quality (p ¼ 0.006),
patient safety (p ¼ 0.05) and ﬁndings fraud/fabrication (p ¼ 0.01), researchers from emerging countries
indicated more conﬁdence than researchers from developed countries. There was also a signiﬁcant
difference in the readiness to adopt RBM between responders of emerging versus developed markets
(p < 0.0001).
Conclusion: This unique study performed across ten emerging and developed countries strongly sup-
ported the need for systematic global training, education, and implementation of RBM regulatory
guidance, with an aim for better safety of subjects and improved quality of clinical trial data. Further-
more, studies with larger sample sizes are recommended to provide an evidence-based approach.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).adhav).
Inc. This is an open access article u1. Introduction
Pharmaceutical industry is plagued by the complexities sur-
rounding research and development. The drug developers seem to
be constantly raging a war to ﬁght against the changing landscape
and the intrinsic and extrinsic factors that lead to an increasednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Flow diagram of the survey methodology.
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limited to, patent expirations, patent cliffs, generic competitors,
drying pipelines, increasingly stringent and complex regulatory
requirements, segmentation of patient populations, data quality
issues and lack of blockbusters to name a few [1,2].
These challenges are paving ways to integrated solutions for the
increase in cost and other inefﬁciencies in the drug development
processes. One of the ﬁrst efforts was made by the FDA in August
2013, by issuing a guidance called “Oversight of Clinical
Investigations-A Risk-Based Approach to Monitoring [3].” RBM is a
quality driven initiative utilizing a ﬂexible approach to monitoring
[4]. This guidance and the implementation is thought to drive
clinical research and monitoring costs down, while maximizing on
the data quality and human research subject protection. Guidance
on RBM practices and methodologies has since expanded globally
with European Medical Agency's (EMA's) reﬂection paper on risk-
based quality management to meet the requirements on ICH (In-
ternational Conference of Harmonization) GCP section 5.1 and the
recent addendum to ICH E6, with recommendation on interna-
tional implementation of innovative approaches to quality risk
management [5,6]. These recommendations and the global foot-
print of new Drug Applications (NDAs) has lead to much discussion
regarding potential cost saving measures for drug developers and
CROs [7,8]. However, there is no pragmatic data available on how
this will beneﬁt global clinical research investigators, their views on
the merits of RBM, and applicability in different cultural and reg-
ulatory settings. At present, there is no robust data at a global level
indicating that investigational sites are ready, trained, and aware to
support the RBM practices. In addition, there is sparse evidence
that indicates the clinical investigators globally have same level of
conﬁdence in the merits or their general perception about the
applicability and adaptability of this approach.
This gap in understanding the beneﬁt to clinical research sites
and their readiness to adopt and implement RBM has the potential
to delay the starting of meaningful clinical trials, and may lead to
the conduct of less efﬁcient trials. This survey research hypothe-
sized that if the researchers/investigators from emerging and
developed countries are surveyed for their perception regarding
proposed merits of RBM, then there may be a signiﬁcant difference
in their understanding based on their age, gender, role, years of
experience and location.
2. Material and method
An electronic, self-administered survey with a total of 12 items
with twenty-seven multi-part questions, including forced choice
and open-ended queries, was developed to collect feedback from
clinical research staff globally. DrugDev, the world's largest con-
sortium of global investigators, was enlisted to validate the ques-
tionnaire, to carry out the survey to maintain conﬁdentiality of the
data and ensuring privacy of the responder's identity. The country
selectionwas random based on the DrugDev databank and research
staff consortium. The population of interest was clinical research
investigators, research coordinators and other staff across the globe
with experience in conducting clinical trials and those who are/
were aware of the RBM or utilized the methodology in one of their
studies. The International Monetary Fund's List was used a refer-
ence to categorize the developed and emerging countries.
The ﬂow diagram in Fig. 1 depicts the research methodology for
survey creation and validation. The methodology utilized was cross
sectional survey analysis. Survey measures used were both quali-
tative (open-ended questions) and quantitative (forced-choice
questions) in nature. To validate the questionnaire, a pre-test of the
survey was conducted with various subject matter experts (in-
vestigators, study coordinators and study monitors) from theclinical research industry who were actively working on studies
utilizing RBM principles. Subject matter experts who validated the
survey instrument were either afﬁliated with DrugDev or were
research investigators or coordinators from outside of this organi-
zation. The respondent's decision to complete the survey was
greatly affected by their interest in the topic but also by the
appearance and clarity of the questionnaire. To handle this bias and
to limit the impact on the overall outcome of success for the project,
these subject matter experts were asked to review the question-
naire for the format, content, interview technique, appearance,
clarity, relevancy, jargon, misrepresentation and bias, etc.
Applicable revisions were made to the questionnaire post this
initial validation. A second validation was performed to attain
feedback on the revised format and content. This attempt included
a different set of industry experts, along with a few randomly
selected individuals from the ﬁrst round. The second round of
validation came back with little to no change and aided in con-
ﬁrming the ﬁnal model of the validated questionnaire. The ques-
tionnaire consisted of ﬁve general questions on demographics and
experience, followed by questions to ascertain if the responders
were aware of RBM. The responders were included in the analysis
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with lack of RBM experience were excluded from the report. The
rest of the questions were based on ﬁve point linkert scale and
focused on the merits of RBM as it relates to clinical trial cost, data
quality, subject safety, readiness to adopt and support RBM, fol-
lowed by two open ended questions on recommendation and
additional thoughts. Responders had to be aware of RBM to
adequately respond to the scope of monitoring practices utilizing
RBM technique. Approximately three thousand randomly selected
DrugDev members from their global investigator network were
invited to participate in the survey. Data collection started from
28th July through 15th September 2014. De-identiﬁed data was
then aggregated for the analysis.
A power analysis technique using PASS sample size calculator
software was applied with the goal to have an estimated sample
size of two thousand surveys sent to the developed countries and
1000 surveys sent to the emerging countries. An 8e15% survey
response rate with alpha of 0.05 was estimated to provide adequate
power to detect the difference between the two types of markets at
85e99%. Continuous variables were reported as means and stan-
dard deviations (SD) and categorical variables were reported as a
percent (%). Fisher's exact test and two-sample t-test were con-
ducted for comparing categorical and continuous variables
respectively between the groups. It was considered statistically
signiﬁcant if the P-value was <0.05. Due to the exploratory nature
of this analysis multiple comparison procedure was not accounted
for. All analyses were conducted using SAS 9.4 (SAS Institute, Cary,
NC).3. Results
Of the 3000 surveys sent globally, 595 surveys were collected
with a total response rate of approximately 20% (sum of dis-
qualiﬁed, partial and complete responses). Responders from
developed countries accounted for approximately 11%. The details
of the response rate in the two groups are summarized in Table 1. Of
these, 595 surveys collected, which included surveys that had
complete response (CR), partial response (PR) and surveys from
those participants who were disqualiﬁed because of their lack of
RBM experience (NE). The CR sample was deﬁned as those that had
completed the survey in its entirety. The PR sample represents
those that answered some questions but not all. NE sample were
those that did not have any exposure to RBM. Those that who did
not completed the survey at all were characterized as no response
(NR). The numbers of surveys with no response was computed by
subtracting the number of disqualiﬁed, partial responses and
complete responses from the total number of surveys sent.
One thousand surveys were sent to the researchers in the
emerging countries (comprised of Argentina, Brazil, China, India,
Russia and South Africa). Of these, 100 completed, 34 partially
completed, and 127 surveys were received who did not haveTable 1
Response rate of the survey across the emerging and developed countries.
Emerging countries n (%)
Total surveys sent 1000
Complete responses (CR) 100 (10)
Partial responses (PR)a 34 (3.4)
Disqualiﬁed/No exposure (NE) 127 (13)
No response (NR) 739 (74)
a There were 80 partial respondents from emerging countries and 56 partial responde
countries clicked the survey but did not answer any questions. 33 and 35 of them answere
(RBM)?” but did not answer other further questions thus excluded from the analysis. 5 an
analysis.experience with RBM. Similarly, two thousand surveys were sent to
researchers in developed countries (Australia, Germany, United
States and United Kingdom). Of these, 137 completed, 35 partially
completed and 162 surveys were received who did not have
experience with RBM. The sum of the disqualiﬁed, partial and
complete responses from both emerging and developed countries
accounted for a total of 595. Of these 595 surveys, 289 were
excluded from analysis as they answered “no” to the survey ques-
tion “are you aware of Risk-Based Monitoring (RBM)?” Partial re-
sponders were also excluded from the analysis. With these above
exclusions, survey results for 237 respondents comprised the basis
of this report. The breakdown of responders in emerging and
developed countries is provided in Fig. 2.
Demographic characteristics of the survey respondents are
given in Table 2. The responders were asked to answer ﬁve de-
mographics questions before answering on their experience with
RBM. Demographic questions included their role in the study,
gender, age, country of residence and experience as it relates to
number of trials that they have worked on. The objectives of these
questions were to evaluate the demographic trends between the
emerging and developed countries and to analyze if the age,
experience and work location had any impact on the opinion of the
researchers when analyzed against their responses for RBM based
questions.
Apart from demographics, the respondents were asked to
answer 3 multipart questions to evaluate their experience and
understanding with regards to how RBM practice relates to
research cost and quality and their readiness to adopt RBM prac-
tices. In addition there were 2 open ended questions for general
feedback on RBM.
Out of 237 responders, 100 were from emerging countries and
137 from developed countries. When looked at by role, themajority
of the responders were clinical research investigators followed by
study coordinators, and staff members. When responses were
compared by sex; in the developed world; the number of male
versus female responders were almost the same; however, in the
emerging countries, there were more male responders than fe-
males, which could be attributed to higher number of male in-
vestigators. There were similar response rates by males in both
regions; however, more females responded to the survey in the
developed countries than emerging countries, which could be due
to a high response rate by research coordinators/nurses. Age ranged
between 30 to over 60 years, of which the majority of the re-
sponders were in their 50's. We observed that older the age group,
the higher the number of responders.
Response rates by countries showed that, in the emerging re-
gion, the highest response rate was from India with 33% and China
had the least response rate of 4%. Brazil, Russia and South America
responded between 17 and 18%, and Argentina reported 11%. In the
developed world, we noticed more variability in the response rate,
with about 64% from the United States, 16, 13 and 7% by Germany,Developed countries n (%) Total n (%)
2000 3000
137 (6.9) 237 (7.9)
35 (1.8) 69 (2.3)
162 (8) 289 (9.6)
1666 (83) 2405 (80.2)
nts from developed countries, 42 from emerging countries and 18 from developed
d demographic questions and the question “Are you aware of Risk BasedMonitoring
d 3 of them answered part of the questions and their responses were included in the
Fig. 2. Details of responses received for this survey.
Table 2
Demographics and Awareness of RBM among responders.
Emerging countries n ¼ 100 (%) Developed countries n ¼ 137 (%) Total n ¼ 237 (%)
Role
Investigator 79 (79) 79 (58) 158 (67)
Coordinator/Research Nurse 16 (16) 39 (28) 55 (23)
Other Site Staff 5 (5) 19 (14) 24 (10)
Gender
Female 37 (37) 72 (53) 109 (46)
Male 63 (63) 65 (47) 128 (54)
Age (years)
<30 3 (3) 6 (4) 9 (4)
31e40 26 (26) 20 (15) 46 (20)
41e50 29 (29) 39 (28) 68 (29)
51e60 26 (26) 49 (36) 75 (32)
>60 16 (16) 23 (17) 39 (17)
Country
Argentina 11 (11) e
Brazil 17 (17) e
China 4 (4) e
India 33 (33) e
Russia 17 (17) e
South Africa 18 (18) e
Australia e 10 (7)
Germany e 22 (16)
United Kingdom e 18 (13)
United States e 87 (64)
Number of Trials involved
Less than 3 6 (6) 4 (3) 10 (4)
3 to 10 37 (37) 24 (18) 61 (26)
Greater than 10 57 (57) 109 (80) 166 (70)
RBM Awareness 100 (100) 137 (100) 237 (100)
I am/have been involved in a study using RBM 33 (33) 69 (50) 100 (43)
I am scheduled to be involved in a study using RBM 10 (10) 19 (13) 29 (11)
I have good knowledge of RBM and its practices 19 (19) 31 (22) 50 (21)
I have general awareness of RBM and its practice 55 (55) 63 (46) 118 (50)
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When assessed, based on involvement in number of trials in the
last 5 years, in the developed world, about 80% of the responders
had participated in more than 10 clinical research trials indicatingsigniﬁcant exposure,, whereas 57% was noted in the emerging
markets suggestive of lesser exposure. We observed a positive
correlation of age and experience with the exposure to RBM and its
core principles.
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exposure to clinical trials. When asked to rate their experiencewith
RBM, 50% reported good knowledge of RBM, and also almost equal
percentage of these responders were/are actively involved in a trial
using RBM approach. We observed an interesting thing that,
although there were 50% responders from developed countries,
only 27% of these responded to having good knowledge of RBM
concept indicating that a signiﬁcant lack of relevant knowledge in
the domain.
On the other hand, responders from emerging countries were
only 33%; however 19% who were involved in clinical trial with
RBM believed that they had good knowledge. These ﬁndings were
indicative and implied that just being involved in a RBM trial does
not necessarily mean one may have good understanding of the
methodology. In addition, it also appeared that there was a varied
understanding and interpretation of what constitutes a good un-
derstanding of RBM, and its applicability and adoptability. The
developed world was more conservative in their response.
Feedback on RBM and research cost by the responder's country
of residence and role is depicted in Table 3. We did not observed
signiﬁcant difference in feedback between the researchers in
developing versus emerging countries (p ¼ 0.20) in regards to their
perception of RBM, and reducing the overall cost of conducting a
clinical research. Responders from emerging countries more
favorably responded than the responders in the developed coun-
tries. Similarly, when asked if RBM will be more effective in
addressing data quality (p ¼ 0.006), patient safety (p ¼ 0.05) and
ﬁndings fraud/fabrication (p ¼ 0.01), researchers from emerging
countries were signiﬁcantly more conﬁdent than their counterpart.
We also found a signiﬁcant difference in perception on readiness to
adopt RBM between responders of emerging versus developed
markets (p < 0.0001).
When, the same questions were analyzed by role, investigators
appeared to have much higher scores than research coordinators
and other site staff, which could be due to their experience with
RBM. The details are provided in Table 4. However, interestingly,
their role did not have signiﬁcant impact on their perception of
RBM, as it relates to research cost, data quality and patient safety.
When the data was analyzed by experience, we did not ﬁnd any
signiﬁcant difference between responders in developed versus
emerging regardless of their experience. This could be attributable
to relatively small sample size in each category.
4. Discussion
To our best of our knowledge, the current analysis offers the
only global characterization of RBM practices and perception ofTable 3
Average scores for questions below by work location.
The Sum Score of RBM For Reducing research related costs
The Sum Score of RBM For Human Subject Protection and Data Quality
The Sum Score of Readiness To Adopt/Support RBM
RBM will better support timely oversight of data by the sponsors/CROs
Sum score of “RBM will be more effective in detecting data quality issues”
and “RBM will be more effective in addressing data quality issues”
Sum score of “RBM will be more efﬁcient in timely detection of patient
safety related data” and “RBM will be more efﬁcient in addressing
patient safety related matter”
Sum score of “RBM will be more effective in detecting fraud and fabrication
of data” and “RBM will be more effective in addressing fraud and fabrication
of data”clinical research staff on its merits, since the launch of the FDA
guidance in 2013. The drug development, especially clinical trials is
a costly affair. The clinical trials monitoring, constitutes between
25% and 30% of the total trial cost [9]. Since RBM was launched
there is a widely accepted perception among clinical research
sponsors and CROs that RBM and its practices will help offset cost,
improve data quality, minimize subject safety related ﬁndings,
reduce data fraud and fabrication.
Given this perception, it is prudent to assess that current RBM
methods are achieving the desired intent of reducing the overall
research cost, protecting patients, and ensuring data integrity. This
transformation will require global commitment and understand-
ing. Although the literature on global perception of RBM in clinical
trials is limited, our ﬁndings appear to derive some interesting
deductions.
The results of our survey revealed that when data was assessed
by location, signiﬁcantly more researchers in the emerging coun-
tries believed in the proposed merits of RBM than researchers in
the developed world (Table 3). Similar trends were seen for ques-
tions related to RBM as it relates to cost, data quality, patient safety,
fraud detection etc. In all cases, researchers from emerging coun-
tries seemed to have more trust in RBM and its proposed merits
then those in the developed world. The survey did shed some light
on the readiness of the researchers to adopt RBM practices globally.
Even though we observed that researchers globally state that they
are ready to adopt and implement RBM practices at their respective
research site, researchers in emerging countries were signiﬁcantly
more conﬁdent in their readiness than researchers in the devel-
oped world.
There was no signiﬁcant difference between the two groups
based on role and experience (Table 4). Thus these variables did not
seem to have impact on their perception and understanding of RBM
practices and implications on research cost, quality and patient
safety. The reasons for the difference based on location are not
clear. It will be interesting to study this further, to understand if
these differences are associated with differences in culture, local
and regional differences in managing clinical trials, or some other
local intrinsic or extrinsic factors. Overall, the notable factor was
that research staff in emerging countries had less experience than
research staff in developed world, but had more trust in RBM and
its merits. We hypothesized that this ﬁnding may be related to the
fact that most of the early pilot work and feedback was from the
developed world and they might have been more skeptical, as they
have seen the hurdles with the current analytics and tools to sup-
port RBM. These analytics and tools will need further reﬁnement
and improvement to get desired outcomes [4,10]. Similarly, the
developed world seemed more conservative in their response thanWork location P-value
Emerging Developed
n Mean SD n Mean SD
100 13.4 3.3 137 12.3 3.9 0.20
100 23.9 6.4 137 21.4 7.1 0.006
100 25.7 4.4 137 22.6 5.2 <0.0001
100 3.6 0.9 134 3.3 1.2 0.01
98 6.9 2.1 136 6.2 2.2 0.01
100 7.0 1.9 134 6.4 2.2 0.05
98 6.6 2.1 131 5.8 2.2 0.01
Table 4
Average score response received for the questions speciﬁc to the role.
Current role P-value
Coordinator/Research nurse Investigator Other site staff
n Mean SD n Mean SD n Mean SD
The Sum Score Of RBM For Reducing research related costs 55 12.7 3.8 158 13.1 3.5 24 11.0 4.3 0.03
The Sum Score Of RBM For Human Subject Protection and Data Quality 55 21.2 6.6 158 23.1 6.7 24 20.7 8.3 0.08
The Sum Score Of Readiness To Adopt/Support RBM 55 23.3 6.0 158 24.2 4.6 24 23.3 6.0 0.48
RBM will better support timely oversight of data by the sponsors/CROs 55 3.2 1.1 156 3.5 1.0 23 3.2 1.3 0.09
Sum score of “RBM will be more effective in detecting data quality issues”
and “RBM will be more effective in addressing data quality issues”
55 5.9 2.1 155 6.7 2.1 24 6.0 2.5 0.03
Sum score of “RBM will be more efﬁcient in timely detection of patient
safety related data” and “RBM will be more efﬁcient in addressing
patient safety related matter”
55 6.2 2.1 156 6.9 2.0 23 6.3 2.4 0.09
Sum score of “RBM will be more effective in detecting fraud and fabrication
of data” and “RBM will be more effective in addressing fraud and fabrication
of data”
53 6.0 2.2 152 6.3 2.1 24 5.4 2.4 0.16
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is an example of an area where provision of additional training and
experience could have a signiﬁcant impact in making a more
informed decision.
Our study was not free from limitations. First, the overall
response rate to our survey was approximately 20%. The United
States had the highest response rate, accounting for 64% of the
overall responses from developed countries. Similarly, in the
emerging countries, India had the highest response rate with 33%,
and China with only 4%, even though a large number of clinical
trials are conducted there. This variability may have resulted in
not capturing some of the country-speciﬁc variances, and the
responding sample may not have been representative of the in-
dustry at large. In addition, the low response rate and relatively
small sample size could have led to a bias in comparisons between
the two representative samples. One of the approaches to address
these limitations would be to quantitatively deﬁne the cost
beneﬁt, data quality and patient safety achieved by a speciﬁc RBM
practice at research sites that are utilizing RBM trials, and then
measure the parameters against research sites that are not using
RBM trials.
5. Conclusion
The present study could be among the ﬁrst to collect evidence
and address gaps in the understanding of RBM from a select group
of researchers globally. The results from the current study inferred
that investigators globally believed that RBM has the potential to
drive the cost of drug development down while ensuring patient
safety and data quality. However, there is variability in the
perception of how RBM impacts drug development costs, data
quality and patient safety which needs further exploration. There
has been signiﬁcant improvement in the types and utility of the
RBM analytics since the inception of this study. It would be bene-
ﬁcial to understand if these technologies have resulted in the
conduct of more cost-efﬁcient clinical trials, with higher quality
data and enhanced patient safety.
In nut shell, further studies involving larger populations and
more evidence is recommended to extrapolate from other pop-
ulations and to discover the transient nature of data quality impact
based on RBM practices globally. This ethos of collaboration be-
tween public, private, government and researchers is critical to
harmonizing RBM practices and international recommendations.
Therefore, it is proposed that a global community of clinical trial
fraternity with various roles and expertise is established to un-
derstand RBM requirements and drive local level pragmatic oper-
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